Search research articles
Contact Us
Filters
Showing results (261-270 of 299) with videos related to
Page
of 30
Sort By:
Journal of the American College of Cardiology
|
June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
David M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
American Journal of Preventive Cardiology
|
July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology
|
August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Heart Journal
|
June 7, 2016
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)
Rishi Puri, Steven E Nissen, Ransi Somaratne, et al.
The New England Journal of Medicine
|
March 17, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, et al.
Journal of the American College of Cardiology
|
February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Lancet (London, England)
|
November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P Giugliano, Nihar R Desai, Payal Kohli, et al.
Journal of the American College of Cardiology
|
February 20, 2007
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial
Piotr Ponikowski, Stefan D Anker, Joanna Szachniewicz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 21, 2011
Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States
Alan R Katz, Alan Y Komeya, Olusegun O Soge, et al.
The Lancet. Diabetes & Endocrinology
|
February 21, 2017
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Frederick J Raal, G Kees Hovingh, Dirk Blom, et al.
Page
of 30
Search research articles
Search
Showing results (261-270 of 299) with videos related to
Sort By:
Page
of 30
Journal of the American College of Cardiology
|
June 15, 2019
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
David M Charytan, Marc S Sabatine, Terje R Pedersen, et al.
American Journal of Preventive Cardiology
|
July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Journal of Preventive Cardiology
|
August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]
Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.
American Heart Journal
|
June 7, 2016
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)
Rishi Puri, Steven E Nissen, Ransi Somaratne, et al.
The New England Journal of Medicine
|
March 17, 2015
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, et al.
Journal of the American College of Cardiology
|
February 11, 2014
Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials
Frederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Lancet (London, England)
|
November 13, 2012
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P Giugliano, Nihar R Desai, Payal Kohli, et al.
Journal of the American College of Cardiology
|
February 20, 2007
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial
Piotr Ponikowski, Stefan D Anker, Joanna Szachniewicz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 21, 2011
Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States
Alan R Katz, Alan Y Komeya, Olusegun O Soge, et al.
The Lancet. Diabetes & Endocrinology
|
February 21, 2017
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Frederick J Raal, G Kees Hovingh, Dirk Blom, et al.
Page
of 30